
Kardigan, Inc.
Sector
Healthcare
Filed
May 26, 2026
About
Kardigan, Inc.
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.
Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve.
We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.
Kardigan, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | May 26, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | May 4, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Mar 26, 2026 | [Cover] Draft Registration Statement |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Tassos Gianakakos
Chief Executive Officer, Director, and Chair
Brianne Puglisi
Chief Financial Officer
Jay Edelberg
Chief Medical Officer
Andy Pasternak
Chief Strategy Officer
John B. Moriarty, Jr.
Chief Legal Officer and Corporate Secretary
Paul Berns
Director
Douglas Giordano
Director
David Meeker, M.D.
Director
Kim Popovits
Director
Tim Walbert
Director